✦ LIBER ✦

Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck

✍ Scribed by David J. Adelstein; Pierre Lavertu; Jerrold P. Saxton; Michelle Secic; Benjamin G. Wood; John R. Wanamaker; Isaac Eliachar; Marshall Strome; Marjorie A. Larto

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 102 KB
Volume: 88
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(20000215)88:4<876::aid-cncr19>3.0.co;2-y

No coin nor oath required. For personal study only.

✦ Synopsis

The current study presents mature results from a Phase III randomized trial comparing radiation therapy and concurrent chemoradiotherapy in patients with resectable American Joint Committee on Cancer Stage III and IV disease.

📜 SIMILAR VOLUMES

A phase III randomized trial comparing c

A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results

✍ David J. Adelstein; Jerrold P. Saxton; Pierre Lavertu; Laurie Tuason; Benjamin G 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

Background. A phase III randomized comparison of radiotherapy alone versus combination chemotherapy and concurrent continuous-course radiotherapy was performed at the Cleveland Clinic Foundation. Methods. Between March 1990 and June 1995, 100 patients with resectable stage III and IV squamous cell

Management of the neck in a randomized t

Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer

✍ Pierre Lavertu; David J. Adelstein; Jerrold P. Saxton; Michelle Secic; John R. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

Background. Treating the neck after organpreservation treatment with radiotherapy or chemoradiotherapy can be problematic. Methods. To develop management guidelines, we reviewed the results of a 100-patient phase-3 trial that had compared outcome after radiotherapy alone with outcome after chemorad

Alternating chemoradiotherapy versus par

Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck : Results from a phase III randomized trial

✍ Renzo Corvò; Marco Benasso; Giuseppe Sanguineti; Rita Lionetto; Almalina Bacigal 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## BACKGROUND. The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone. The purpose of this randomized trial was to compare the

High-dose intra-arterial cisplatin and c

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study

✍ William F. Regine; Joseph Valentino; William John; Gayle Storey; David Sloan; Da 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

Adjuvant chemotherapy with Cis-diamminod

Adjuvant chemotherapy with Cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck

✍ David A. Decker; Anibal Drelichman; John Jacobs; Judith Hoschner; Jeannie Kinzie 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 1 views

Final report of a phase II evaluation of

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)

✍ Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.